Connection
Matthew Greenhawt to Markov Chains
This is a "connection" page, showing publications Matthew Greenhawt has written about Markov Chains.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.677 |
|
|
|
-
Shaker MS, Mosnaim G, Oppenheimer J, Stukus D, Abrams EM, Greenhawt M. Health and Economic Outcomes of Home Maintenance Allergen Immunotherapy in Select Patients with High Health Literacy during the COVID-19 Pandemic: A Cost-Effectiveness Analysis During Exceptional Times. J Allergy Clin Immunol Pract. 2020 Jul - Aug; 8(7):2310-2321.e4.
Score: 0.171
-
Shaker MS, Greenhawt MJ. Analysis of Value-Based Costs of Undesignated School Stock Epinephrine Policies for Peanut Anaphylaxis. JAMA Pediatr. 2019 02 01; 173(2):169-175.
Score: 0.156
-
Shaker M, Verma K, Greenhawt M. The health and economic outcomes of early egg introduction strategies. Allergy. 2018 11; 73(11):2214-2223.
Score: 0.153
-
Shaker M, Stukus D, Chan ES, Fleischer DM, Spergel JM, Greenhawt M. "To screen or not to screen": Comparing the health and economic benefits of early peanut introduction strategies in five countries. Allergy. 2018 Aug; 73(8):1707-1714.
Score: 0.149
-
Sun D, Heimall JR, Greenhawt MJ, Bunin NJ, Shaker MS, Romberg N. Cost Utility of Lifelong Immunoglobulin Replacement Therapy vs Hematopoietic Stem Cell Transplant to Treat Agammaglobulinemia. JAMA Pediatr. 2022 02 01; 176(2):176-184.
Score: 0.048